<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117726</url>
  </required_header>
  <id_info>
    <org_study_id>ARDS2014</org_study_id>
    <nct_id>NCT02117726</nct_id>
  </id_info>
  <brief_title>Impact of Various Sedation Regimens on the Incidence of Delirium</brief_title>
  <official_title>Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <brief_summary>
    <textblock>
      Sedation drugs that are commonly used in ICU in treatment of ARDS, includes propofol,&#xD;
      midazolam and dexmedetomidine . Among these, both dexmedetomidine and propofol have been&#xD;
      reported to be used together with midazolam in ICU and the combination of propofol and&#xD;
      midazolam is most commonly used, but things follow include a high incidence rate of delirium,&#xD;
      But the combination of midazolam and dexmedetomidine may have complementary advantages and&#xD;
      could have be a better choice for sedation. In this study, we attempted to observe the&#xD;
      effects of two different drug regimens on delirium incidence rates in severe ARDS patients' :&#xD;
      midazolam and propofol vs propofol and dexmedetomidine .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rates and duration of delirium</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Incidence rates and duration of delirium within 14 days after initiation of sedation with dexmedetomidine or propofol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation interruption</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Eye opening according to the voice orders, eye tracking, clenching fist and nodding are involved in assessment, patients could do 3 of those or more is deemed as conscious and taken in delirium assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation therapy effect</measure>
    <time_frame>up to 7 days</time_frame>
    <description>The frequency of assessment whose score fall within the target range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalized days in ICU</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rates</measure>
    <time_frame>28 days</time_frame>
    <description>Patients' death rates with a follow-up of 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of patients self-extubation</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection speed, total dose and injection of sedatives in different groups.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional dose of fentanyl and midazolam</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of diuretic, antiemetic, hypoglycemic, beta-receptor antagonist and vasoactive agents.</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation degree of HR, RR, BP and SpO2</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine,midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4Î¼g/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol,midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine,midazolam</intervention_name>
    <arm_group_label>Dexmedetomidine,midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol,midazolam</intervention_name>
    <arm_group_label>Propofol,midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects willing to give written informed consent.&#xD;
&#xD;
          -  Mild, moderate or severe ARDS patients demanding invasive mechanical ventilation.&#xD;
&#xD;
          -  Subjects whose expected time of mechanical ventilation is longer than 24 hours.&#xD;
&#xD;
          -  Subjects aged between 18 and 70.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with extremely unstable circulation, whose SBP lower than 90mmHg after volume&#xD;
             expansion or pressor agent treatment.&#xD;
&#xD;
          -  Subjects with extremely unstable circulation, whose SBP lower than 90mmHg after volume&#xD;
             expansion or pressor agent treatment.&#xD;
&#xD;
          -  Subjects with heart rates less than 50 beats per minute.&#xD;
&#xD;
          -  Subjects with second or third degree atrioventricular block.&#xD;
&#xD;
          -  Subjects with serious cerebral injury, severe neurologic disorder (e.g acute stroke,&#xD;
             uncontrolled epilepsy and severe dementia) or coma.&#xD;
&#xD;
          -  Subjects with acute or severe liver disease (Child-Pugh class C), see attachment 2.&#xD;
&#xD;
          -  ARDS patients caused by pulmonary fibrosis or COPD.&#xD;
&#xD;
          -  Subjects on all types hemodialysis.&#xD;
&#xD;
          -  Subjects with neuromuscular system disease, alcohol withdrawal syndrome or mental&#xD;
             disease before entrance of ICU.&#xD;
&#xD;
          -  Subjects suspected of narcotic analgesics abusing.&#xD;
&#xD;
          -  Subjects needing neuromuscular blocking agents (except intubation).&#xD;
&#xD;
          -  Subjects allergic to investigational products or with other contraindication.&#xD;
&#xD;
          -  Subjects who are breastfeeding or pregnant&#xD;
&#xD;
          -  Subjects participated in other study within 30 days before entrance of ICU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HeNan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fang Xing, physician</last_name>
      <phone>400-0371-818</phone>
      <email>xfsally2007@163.com</email>
    </contact>
    <investigator>
      <last_name>Fang Xing, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250033</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengen Ma</last_name>
      <phone>+86 15153169727</phone>
      <email>chengen99@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haiwei Yang, Physician</last_name>
      <phone>+86 13518675416</phone>
      <email>yhw200465@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>252000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiejun Wu, physician</last_name>
      <phone>+86 13306352913</phone>
      <email>wtj0721@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tingfa Zhou</last_name>
      <phone>+86 13013538061</phone>
      <email>zhoutingfa66@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Weifang Medical University</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peirong Zhang, Physician</last_name>
      <phone>15269600599</phone>
      <email>zhangpeirong@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Zibo</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>255000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shifu Wang, Physician</last_name>
      <phone>18678186866</phone>
      <email>wsficu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wangchunting</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Sedation;</keyword>
  <keyword>ARDS;</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Hypnotics</keyword>
  <keyword>Antianxiety Drugs</keyword>
  <keyword>Causing</keyword>
  <keyword>Adverse Effects</keyword>
  <keyword>Therapeutic Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

